If you have traveled to any area in the US that is considered a “hot spot” with increasing amount of cases of COVID please alert our office before coming in for any appointment. All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are now available for routine office visits.

FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Neelima Denduluri, MD, FASCO

VCS Physicians

Neelima Denduluri, MD, FASCO Headshot

My profession and expertise in oncology care affords me a very special and unique opportunity to help alleviate a patient’s stress and uncertainty at a most challenging and vulnerable time in their life. By combining exceptional patient care with the most cutting edge treatments, I am able to tailor each patient’s plan of care specifically to meet their individual needs and concerns.

Work and Credentials:

Primary Location

Arlington Office

Position

Medical Oncologist

Board Certification

Medical Oncology and Internal Medicine

Fellowship

National Cancer Institute, Medical Oncology

Residency

Georgetown University Medical Center

Medical School

Louisiana State University Medical Center

Special Interests

Breast Cancer

Dr. Neelima Denduluri earned her medical degree from the Louisiana State University Medical Center, where she served as President of the American Medical Student Association. Upon graduation she received the “Exemplar of Desirable Attitudes of the Physician Towards His Patients” award, which is bestowed upon one graduating senior. She completed her Internal Medicine residency at Georgetown University Medical Center. During her fellowship at the National Cancer Institute, she was honored with the distinction of serving as Chief Fellow. She later served as Assistant Clinical Investigator and Staff Physician at NCI before joining Virginia Cancer Specialists.

Dr. Denduluri remains highly involved in the local community by participating in community outreach, speaking to support groups, and volunteering at the Arlington Free Clinic since 1999. She has consistently been named as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine, and she has been featured in both local and national media for her expertise in breast cancer.

In addition to her passion for patient care, Dr. Denduluri’s dedication to the advancement of medicine has led her to take on multiple leadership roles, including: Associate Chair of the US Oncology Breast Cancer Research Committee and Cancer Committee Chairman at Virginia Hospital Center. Dr. Denduluri also currently serves as the CO Director of the Virginia Cancer Specialists Research Program and is on a steering committee member for NAPBC accreditation for the Reinsch Pierce Family Center for Breast Health.

Dr. Denduluri continues to be active in medical education, currently serving as Clinical Assistant Professor at Georgetown University Medical Center. She has also taught attending students and residents of Virginia Commonwealth University, as well as oncology fellows at the National Navel Medical Center in Bethesda, MD. Dr. Denduluri has published multiple articles and abstracts, and her work has been presented at various national meetings, including the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium.

Dr. Denduluri is fluent in English, Spanish, and Telugu (an Indian language).

 



Twitter: @ndenduluri1

Physician Publications

October 3, 2020

BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study

Read More
March 15, 2020

Symptom Burden Among Older Breast Cancer Survivors: The Thinking and Living With Cancer (TLC) Study

Read More
February 27, 2020

Pembrolizumab for Early Triple-Negative Breast Cancer

Read More

More Publications by Neelima Denduluri, MD, FASCO

February 13, 2020

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Read More
December 20, 2019

Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.

Read More
December 16, 2019

ASCO Clinical Practice Guideline Endorsements and Adaptations.

Read More
November 28, 2019

When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.

Read More
September 25, 2019

Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype.

Read More
August 21, 2019

Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.

Read More
June 7, 2019

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.

Read More
March 11, 2019

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Read More
March 1, 2019

Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer Survivors.

Read More
October 3, 2018

Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.

Read More
May 1, 2018

Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.

Read More
December 18, 2017

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Read More
December 1, 2017

Lifestyle Interventions to Improve Cardiorespiratory Fitness and Reduce Breast Cancer Recurrence.

Read More
July 11, 2017

Patient Case Lessons: Endocrine Management of Advanced Breast Cancer

Read More
June 7, 2017

Patient Case Lessons: Endocrine Management of Advanced Breast Cancer.

Read More
April 3, 2017

American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations

Read More
February 10, 2017

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.

Read More
February 6, 2017

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Read More
February 6, 2017

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

Read More
July 27, 2016

Innovations in American Society of Clinical Oncology Practice Guideline Development.

Read More
July 27, 2016

Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary.

Read More
July 27, 2016

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Read More
November 1, 2015

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Read More
May 20, 2014

Coginitive Impairments in Older Breast Cancer Patients Prior to Systemic Therapy: Is There an Interaction between Cancer and Comorbidity

Read More
December 1, 2013

Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Read More
June 3, 2013

Bridging to survivorship in breast cancer: learning how treatment impacts mental health among early stage breast cancer survivors.

Read More
June 3, 2013

Bridging to Survivorship in Breast Cancer-How BMI Weighs In?

Read More
February 2, 2013

Read More
December 15, 2012

Read More
December 15, 2012

Read More
December 15, 2012

Read More
September 13, 2012

Risk of acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy for early breast cancer in the community setting.

Read More
June 1, 2012

Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer

Read More
September 8, 2011

Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts)

Read More
June 1, 2011

Ixabepilone: Clinical Role in Metastatic Breast Cancer

Read More

Clinical Trials (7)

Clinical Trial 20284

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)


Clinical Trial 19058

CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).


Clinical Trial 19054

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)


Clinical Trial DS8201-A-U303

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS


Clinical Trial 18282

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)


Clinical Trial DS8201-A-U301

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A (TRASTUZUMAB DERUXTECAN), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES, INCLUDING T-DM1

All Clinical Trials for Neelima Denduluri, MD, FASCO

Clinical Trial 20284

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)

Locations:

Loudoun Office

ClinicalTrials.gov ID:

NCT04539938

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19058

CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03701334

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19054

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

ClinicalTrials.gov ID:

NCT03975647

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS8201-A-U303

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03734029

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18282

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

ClinicalTrials.gov ID:

NCT03901339

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS8201-A-U301

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A (TRASTUZUMAB DERUXTECAN), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES, INCLUDING T-DM1

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03523585

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18232

(AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03719326

ClinicalTrials.gov Link:

Click Here

Primary Location

Arlington Office Office

Arlington Office

Learn More

Other Locations

Awards

February 1, 2020

2020 Northern Virginia Magazine Top Doctors


November 1, 2020

Washingtonian Magazine top Doctors 2020


November 1, 2019

2019 Washingtonian magazine Top Doctors


January 1, 2019

Northern Virginia Magazine Top Doctor 2019


January 1, 2018

2018 Washingtonian Magazine Top Doctor Nomination


November 30, 2020
Virginia Living Magazine Top Doctor 2018

Top Doctors Virginia Living Magazine 2018


January 1, 2018
Northern Virginia Magazine 2018 Top Doctor

Northern Virginia Magazine Top Doctors 2018


September 9, 2016
Washingtonian Magazine

Top Doctor 2016


September 1, 2015
Washingtonian Magazine

Washingtonian Top Doctor 2015


February 1, 2015
Northern Virginia Magazine

Top Doctor 2015


January 31, 2014
Northern Virginia Magazine

Top Doctor 2014